HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40

Benzinga Newsdesk www.benzinga.com Positive 77.9%

Neg 0% Neu 0% Pos 77.9%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $38 to $40.